Evaluating the comparability of osteoporosis treatments using propensity score and negative control outcome methods in UK and Denmark electronic health record databases
© The Author(s) [2024]. Published by Oxford University Press on behalf of the American Society for Bone and Mineral Research..
Evidence on the comparative effectiveness of osteoporosis treatments is heterogeneous. This may be attributed to different populations and clinical practice, but also to differing methodologies ensuring comparability of treatment groups before treatment effect estimation and the amount of residual confounding by indication. This study assessed the comparability of denosumab vs oral bisphosphonate (OBP) groups using propensity score (PS) methods and negative control outcome (NCO) analysis. A total of 280 288 women aged ≥50 years initiating denosumab or OBP in 2011-2018 were included from the UK Clinical Practice Research Datalink (CPRD) and the Danish National Registries (DNR). Balance of observed covariates was assessed using absolute standardised mean difference (ASMD) before and after PS weighting, matching, and stratification, with ASMD >0.1 indicating imbalance. Residual confounding was assessed using NCOs with ≥100 events. Hazard ratio (HR) and 95% confidence interval (CI) between treatment and NCO was estimated using Cox models. Presence of residual confounding was evaluated with two approaches1: >5% of NCOs with 95% CI excluding 1,2 >5% of NCOs with an upper CI <0.75 or lower CI >1.3. The number of imbalanced covariates before adjustment (CPRD 22/87; DNR 18/83) decreased, with 2-11% imbalance remaining after weighting, matching or stratification. Using approach 1, residual confounding was present for all PS methods in both databases (≥8% of NCOs), except for stratification in DNR (3.8%). Using approach 2, residual confounding was present in CPRD with PS matching (5.3%) and stratification (6.4%), but not with weighting (4.3%). Within DNR, no NCOs had HR estimates with upper or lower CI limits beyond the specified bounds indicating residual confounding for any PS method. Achievement of covariate balance and determination of residual bias were dependent upon several factors including the population under study, PS method, prevalence of NCO, and the threshold indicating residual confounding.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research - (2024) vom: 15. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tan, Eng Hooi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Confounding |
|---|
| Anmerkungen: |
Date Revised 15.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1093/jbmr/zjae059 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371086272 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371086272 | ||
| 003 | DE-627 | ||
| 005 | 20240415234816.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240415s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/jbmr/zjae059 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1376.xml |
| 035 | |a (DE-627)NLM371086272 | ||
| 035 | |a (NLM)38619297 | ||
| 035 | |a (PII)zjae059 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tan, Eng Hooi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluating the comparability of osteoporosis treatments using propensity score and negative control outcome methods in UK and Denmark electronic health record databases |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © The Author(s) [2024]. Published by Oxford University Press on behalf of the American Society for Bone and Mineral Research. | ||
| 520 | |a Evidence on the comparative effectiveness of osteoporosis treatments is heterogeneous. This may be attributed to different populations and clinical practice, but also to differing methodologies ensuring comparability of treatment groups before treatment effect estimation and the amount of residual confounding by indication. This study assessed the comparability of denosumab vs oral bisphosphonate (OBP) groups using propensity score (PS) methods and negative control outcome (NCO) analysis. A total of 280 288 women aged ≥50 years initiating denosumab or OBP in 2011-2018 were included from the UK Clinical Practice Research Datalink (CPRD) and the Danish National Registries (DNR). Balance of observed covariates was assessed using absolute standardised mean difference (ASMD) before and after PS weighting, matching, and stratification, with ASMD >0.1 indicating imbalance. Residual confounding was assessed using NCOs with ≥100 events. Hazard ratio (HR) and 95% confidence interval (CI) between treatment and NCO was estimated using Cox models. Presence of residual confounding was evaluated with two approaches1: >5% of NCOs with 95% CI excluding 1,2 >5% of NCOs with an upper CI <0.75 or lower CI >1.3. The number of imbalanced covariates before adjustment (CPRD 22/87; DNR 18/83) decreased, with 2-11% imbalance remaining after weighting, matching or stratification. Using approach 1, residual confounding was present for all PS methods in both databases (≥8% of NCOs), except for stratification in DNR (3.8%). Using approach 2, residual confounding was present in CPRD with PS matching (5.3%) and stratification (6.4%), but not with weighting (4.3%). Within DNR, no NCOs had HR estimates with upper or lower CI limits beyond the specified bounds indicating residual confounding for any PS method. Achievement of covariate balance and determination of residual bias were dependent upon several factors including the population under study, PS method, prevalence of NCO, and the threshold indicating residual confounding | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Osteoporosis | |
| 650 | 4 | |a confounding | |
| 650 | 4 | |a fracture | |
| 650 | 4 | |a negative control outcome | |
| 650 | 4 | |a propensity score | |
| 700 | 1 | |a Rathod-Mistry, Trishna |e verfasserin |4 aut | |
| 700 | 1 | |a Strauss, Victoria Y |e verfasserin |4 aut | |
| 700 | 1 | |a O'Kelly, James |e verfasserin |4 aut | |
| 700 | 1 | |a Giorgianni, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Baxter, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Brunetti, Vanessa C |e verfasserin |4 aut | |
| 700 | 1 | |a Pedersen, Alma Becic |e verfasserin |4 aut | |
| 700 | 1 | |a Ehrenstein, Vera |e verfasserin |4 aut | |
| 700 | 1 | |a Prieto-Alhambra, Daniel |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research |d 1991 |g (2024) vom: 15. Apr. |w (DE-627)NLM012611115 |x 1523-4681 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:15 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/jbmr/zjae059 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 15 |c 04 | ||